Translating insights from the cancer genome into clinical practice

Lynda Chin, Joe Gray

Research output: Contribution to journalArticle

213 Citations (Scopus)

Abstract

Cancer cells have diverse biological capabilities that are conferred by numerous genetic aberrations and epigenetic modifications. Today's powerful technologies are enabling these changes to the genome to be catalogued in detail. Tomorrow is likely to bring a complete atlas of the reversible and irreversible alterations that occur in individual cancers. The challenge now is to work out which molecular abnormalities contribute to cancer and which are simply 'noise' at the genomic and epigenomic levels. Distinguishing between these will aid in understanding how the aberrations in a cancer cell collaborate to drive pathophysiology. Past successes in converting information from genomic discoveries into clinical tools provide valuable lessons to guide the translation of emerging insights from the genome into clinical end points that can affect the practice of cancer medicine.

Original languageEnglish (US)
Pages (from-to)553-563
Number of pages11
JournalNature
Volume452
Issue number7187
DOIs
StatePublished - Apr 3 2008
Externally publishedYes

Fingerprint

Genome
Neoplasms
Epigenomics
Atlases
Noise
Medicine
Technology

ASJC Scopus subject areas

  • General

Cite this

Translating insights from the cancer genome into clinical practice. / Chin, Lynda; Gray, Joe.

In: Nature, Vol. 452, No. 7187, 03.04.2008, p. 553-563.

Research output: Contribution to journalArticle

Chin, Lynda ; Gray, Joe. / Translating insights from the cancer genome into clinical practice. In: Nature. 2008 ; Vol. 452, No. 7187. pp. 553-563.
@article{e32bdedbac6d4c76920aa0f3bde24510,
title = "Translating insights from the cancer genome into clinical practice",
abstract = "Cancer cells have diverse biological capabilities that are conferred by numerous genetic aberrations and epigenetic modifications. Today's powerful technologies are enabling these changes to the genome to be catalogued in detail. Tomorrow is likely to bring a complete atlas of the reversible and irreversible alterations that occur in individual cancers. The challenge now is to work out which molecular abnormalities contribute to cancer and which are simply 'noise' at the genomic and epigenomic levels. Distinguishing between these will aid in understanding how the aberrations in a cancer cell collaborate to drive pathophysiology. Past successes in converting information from genomic discoveries into clinical tools provide valuable lessons to guide the translation of emerging insights from the genome into clinical end points that can affect the practice of cancer medicine.",
author = "Lynda Chin and Joe Gray",
year = "2008",
month = "4",
day = "3",
doi = "10.1038/nature06914",
language = "English (US)",
volume = "452",
pages = "553--563",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7187",

}

TY - JOUR

T1 - Translating insights from the cancer genome into clinical practice

AU - Chin, Lynda

AU - Gray, Joe

PY - 2008/4/3

Y1 - 2008/4/3

N2 - Cancer cells have diverse biological capabilities that are conferred by numerous genetic aberrations and epigenetic modifications. Today's powerful technologies are enabling these changes to the genome to be catalogued in detail. Tomorrow is likely to bring a complete atlas of the reversible and irreversible alterations that occur in individual cancers. The challenge now is to work out which molecular abnormalities contribute to cancer and which are simply 'noise' at the genomic and epigenomic levels. Distinguishing between these will aid in understanding how the aberrations in a cancer cell collaborate to drive pathophysiology. Past successes in converting information from genomic discoveries into clinical tools provide valuable lessons to guide the translation of emerging insights from the genome into clinical end points that can affect the practice of cancer medicine.

AB - Cancer cells have diverse biological capabilities that are conferred by numerous genetic aberrations and epigenetic modifications. Today's powerful technologies are enabling these changes to the genome to be catalogued in detail. Tomorrow is likely to bring a complete atlas of the reversible and irreversible alterations that occur in individual cancers. The challenge now is to work out which molecular abnormalities contribute to cancer and which are simply 'noise' at the genomic and epigenomic levels. Distinguishing between these will aid in understanding how the aberrations in a cancer cell collaborate to drive pathophysiology. Past successes in converting information from genomic discoveries into clinical tools provide valuable lessons to guide the translation of emerging insights from the genome into clinical end points that can affect the practice of cancer medicine.

UR - http://www.scopus.com/inward/record.url?scp=41649109807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41649109807&partnerID=8YFLogxK

U2 - 10.1038/nature06914

DO - 10.1038/nature06914

M3 - Article

C2 - 18385729

AN - SCOPUS:41649109807

VL - 452

SP - 553

EP - 563

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7187

ER -